Recipharm has established a dedicated taskforce to manage the potential impact of Brexit on its organization.
With less than a year until the UK exits the European Union (EU), the Sweden headquartered global CDMO is focused on managing the transition with minimal impact to its operations and customers.
The formation of the ‘Brexit taskforce’ will see Recipharm prioritize its preparations and invest in the necessary capabilities and equipment within its UK and European facilities to ensure seamless operations post March 2019.
Commenting on the announcement, Thomas Beck, Senior Vice President Quality Management at Recipharm, said “While many stakeholders in the pharma industry are campaigning for a ‘soft’ exit from the EU, there is a risk that the complexity of the regulatory landscape will increase dramatically if a ‘hard’ Brexit takes place. Consequently, we are preparing for all eventualities.”
To strengthen its organization ahead of Brexit, Recipharm has plans to recruit more staff in laboratory and regulatory roles to meet the additional analytical, release testing and administration requirements that are expected.
Recipharm serves 450+ customers from development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US.